Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acceptance and Commitment Therapy for people living with motor neuron disease: an uncontrolled feasibility study.
Gould RL, Rawlinson C, Thompson B, Weeks K, Gossage-Worrall R, Cantrill H, Serfaty MA, Graham CD, McCracken LM, White D, Howard RJ, Bursnall M, Bradburn M, Al-Chalabi A, Orrell R, Chhetri SK, Noad R, Radunovic A, Williams T, Young CA, Dick D, Lawrence V, Goldstein LH, Young T, Ealing J, McLeod H, Williams N, Weatherly H, Cave R, Chiwera T, Pagnini F, Cooper C, Shaw PJ, McDermott CJ; and the COMMEND Collaboration Group. Gould RL, et al. Among authors: chiwera t. Pilot Feasibility Stud. 2023 Jul 7;9(1):116. doi: 10.1186/s40814-023-01354-7. Pilot Feasibility Stud. 2023. PMID: 37420261 Free PMC article.
Comparison Of King's Clinical Staging In Multinational Amyotrophic Lateral Sclerosis Cohorts.
Balendra R, Jones AR, Al Khleifat A, Chiwera T, Wicks P, Young CA, Shaw PJ, Turner MR, Leigh PN, Al-Chalabi A. Balendra R, et al. Among authors: chiwera t. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Feb;24(1-2):71-81. doi: 10.1080/21678421.2022.2090847. Epub 2022 Jul 19. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 35852375 Free article.
The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis.
Kelly M, Lavrov A, Garcia-Gancedo L, Parr J, Hart R, Chiwera T, Shaw CE, Al-Chalabi A, Marsden R, Turner MR, Talbot K. Kelly M, et al. Among authors: chiwera t. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Nov;21(7-8):563-573. doi: 10.1080/21678421.2020.1773501. Epub 2020 Jun 23. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 32573278
ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS.
Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, Colville S, Heverin M, Mays I, Pal S, Pender N, Pinto-Grau M, Radakovic R, Shaw CE, Stephenson L, Swingler R, Vajda A, Al-Chalabi A, Hardiman O, Abrahams S. Crockford C, et al. Among authors: chiwera t. Neurology. 2018 Oct 9;91(15):e1370-e1380. doi: 10.1212/WNL.0000000000006317. Epub 2018 Sep 12. Neurology. 2018. PMID: 30209236 Free PMC article.
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chiò A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Miller TM, et al. N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705. N Engl J Med. 2022. PMID: 36129998 Free article. Clinical Trial.
Correlations between measures of ALS respiratory function: is there an alternative to FVC?
Murray D, Rooney J, Al-Chalabi A, Bunte T, Chiwera T, Choudhury M, Chio A, Fenton L, Fortune J, Maidment L, Manera U, Mcdermott C, Meldrum D, Meyjes M, Tattersall R, Torrieri MC, Van Damme P, Vanderlinden E, Wood C, Van Den Berg LH, Hardiman O. Murray D, et al. Among authors: chiwera t. Amyotroph Lateral Scler Frontotemporal Degener. 2021 Nov;22(7-8):495-504. doi: 10.1080/21678421.2021.1908362. Epub 2021 Sep 30. Amyotroph Lateral Scler Frontotemporal Degener. 2021. PMID: 34590504